Skip to search formSkip to main contentSkip to account menu

GLP-1 Receptor Agonist [EPC]

Known as: GLP-1 Receptor Agonist, Glucagon-like Peptide 1 Receptor Agonist, Glucagon-like Peptide-1 Receptor Agonist 
National Institutes of Health

Related topics

Related topics

2 relations
Glucagon-Like Peptide 1analogs & derivatives

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Metabolic and endocrine effects of SGLT 2 inhibition
Lundkvist, P. 2019. Metabolic and endocrine effects of SGLT2 inhibition. Digital Comprehensive Summaries of Uppsala Dissertations… 
Review
2019
Review
2019
PANCREATIC SAFETY IN STUDIES OF THE GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONIST ALBIGLUTIDE.
OBJECTIVE Albiglutide, a glucagon-like peptide-1 receptor agonist (GLP-1RA), reduces glycated hemoglobin (HbA1c) with a low risk… 
2019
2019
Diabetic cases controlled with low carbohydrate diet (LCD) and GLP-1 receptor agonist (GLP-1 RA)
Recent treatment for type 2 diabetes mellitus (T2DM) has included glucagon-like peptide-1 receptor agonist (GLP-1 RA), indicating… 
Review
2018
Review
2018
Albiglutide for the management of type 2 diabetes
ABSTRACT Introduction: Albiglutide is a long acting GLP-1 receptor agonist (GLP-1 RA) administered by weekly injection and… 
2018
2018
IGlarLixi (insulina glargine U100/lixisenatide): nuovo approccio terapeutico combinato nella gestione del diabete tipo 2
Many type 2 diabetes patients need insulin treatment to achieve a significant improvement of blood glucose profile and reach the… 
2017
2017
Lessons from a cardiovascular outcome trial with liraglutide in type 2 diabetes
Cardiovascular disease (CVD) is the leading cause of death and one of the common diabetes-related complications in patients with… 
Review
2017
Review
2017
The safety of albiglutide for the treatment of type 2 diabetes
ABSTRACT Introduction: Albiglutide is a marketed long acting GLP-1 receptor agonist (GLP-1 RA) administered by weekly injection… 
Review
2017
Review
2017
Glucagon like Peptide-1(GLP-1) a Novel Therapeutic Strategy in Non-Alcoholic Fatty Liver Disease (NAFLD)
Non-alcoholic fatty liver disease (NAFLD) is a main cause of liver disease and its global prevalence is estimated to be 24%. At… 
2016
2016
Clinical and Patient-Related Variables Associated with Initiating GLP-1 Receptor Agonist Therapy in Type 2 Diabetes Patients in Primary Care in Germany
Aims To investigate real-world clinical and patient-related variables associated with initiating GLP-1 receptor agonist (GLP-1RA… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)